BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ellwanger JH, Kulmann-Leal B, Kaminski VL, Rodrigues AG, Bragatte MAS, Chies JAB. Beyond HIV infection: Neglected and varied impacts of CCR5 and CCR5Δ32 on viral diseases. Virus Res 2020;286:198040. [PMID: 32479976 DOI: 10.1016/j.virusres.2020.198040] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 5.7] [Reference Citation Analysis]
Number Citing Articles
1 Crespo F. Ongoing Evolution. A Companion to Biological Anthropology 2023. [DOI: 10.1002/9781119828075.ch16] [Reference Citation Analysis]
2 Ellwanger JH, Kulmann-Leal B, Ziliotto M, Chies JAB. HIV Infection, Chromosome Instability, and Micronucleus Formation. Viruses 2023;15. [PMID: 36680195 DOI: 10.3390/v15010155] [Reference Citation Analysis]
3 Hillman T. A Predictive Model for Identifying the Most Effective Anti-CCR5 Monoclonal Antibody. Arch Pharm Pract 2023;14:40-49. [DOI: 10.51847/d9m2zufqr4] [Reference Citation Analysis]
4 Tuncel B, Kaygusuz S, Sayın Kocakap DB, Aksoy E, Azkur AK. Do CCR5 (CCR5Δ32) and TLR3 (RS5743313) gene polymorphisms prevent chronic hepatitis B infection? J Med Virol 2023;95:e28376. [PMID: 36478230 DOI: 10.1002/jmv.28376] [Reference Citation Analysis]
5 Gupta K, Kaur G, Pathak T, Banerjee I. Systematic review and meta-analysis of human genetic variants contributing to COVID-19 susceptibility and severity. Gene 2022;844:146790. [PMID: 35987511 DOI: 10.1016/j.gene.2022.146790] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 8.0] [Reference Citation Analysis]
6 Ellwanger JH, Secchi M, Aliberti J, Vangelista L. Editorial: CCR5: A receptor at the center stage in infection. Front Immunol 2022;13:1054430. [DOI: 10.3389/fimmu.2022.1054430] [Reference Citation Analysis]
7 Schmidt JK, Reynolds MR, Golos TG, Slukvin II. CRISPR/Cas9 genome editing to create nonhuman primate models for studying stem cell therapies for HIV infection. Retrovirology 2022;19:17. [PMID: 35948929 DOI: 10.1186/s12977-022-00604-5] [Reference Citation Analysis]
8 Freen-van Heeren JJ. Closing the Door with CRISPR: Genome Editing of CCR5 and CXCR4 as a Potential Curative Solution for HIV. BioTech 2022;11:25. [DOI: 10.3390/biotech11030025] [Reference Citation Analysis]
9 van Eekeren LE, Matzaraki V, Zhang Z, van de Wijer L, Blaauw MJT, de Jonge MI, Vandekerckhove L, Trypsteen W, Joosten LAB, Netea MG, de Mast Q, Koenen HJPM, Li Y, van der Ven AJAM. People with HIV have higher percentages of circulating CCR5+ CD8+ T cells and lower percentages of CCR5+ regulatory T cells. Sci Rep 2022;12:11425. [PMID: 35794176 DOI: 10.1038/s41598-022-15646-0] [Reference Citation Analysis]
10 Jasinska AJ, Pandrea I, Apetrei C. CCR5 as a Coreceptor for Human Immunodeficiency Virus and Simian Immunodeficiency Viruses: A Prototypic Love-Hate Affair. Front Immunol 2022;13:835994. [PMID: 35154162 DOI: 10.3389/fimmu.2022.835994] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
11 Kulmann-Leal B, Ellwanger JH, Chies JAB. CCR5Δ32 in Brazil: Impacts of a European Genetic Variant on a Highly Admixed Population. Front Immunol 2021;12:758358. [PMID: 34956188 DOI: 10.3389/fimmu.2021.758358] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Kang W, Sun Y. Moving Toward a Functional Cure for HIV-1. Infectious Diseases & Immunity 2021;1:161-168. [DOI: 10.1097/id9.0000000000000025] [Reference Citation Analysis]
13 Fischer JC, Schmidt AG, Bölke E, Uhrberg M, Keitel V, Feldt T, Jensen B, Häussinger D, Adams O, Schneider EM, Balz V, Enczmann J, Rox J, Hermsen D, Schulze-Bosse K, Kindgen-Milles D, Knoefel WT, van Griensven M, Haussmann J, Tamaskovics B, Plettenberg C, Scheckenbach K, Corradini S, Pedoto A, Maas K, Schmidt L, Grebe O, Esposito I, Ehrhardt A, Peiper M, Buhren BA, Calles C, Stöhr A, Lichtenberg A, Freise NF, Lutterbeck M, Rezazadeh A, Budach W, Matuschek C. Association of HLA genotypes, AB0 blood type and chemokine receptor 5 mutant CD195 with the clinical course of COVID-19. Eur J Med Res 2021;26:107. [PMID: 34530915 DOI: 10.1186/s40001-021-00560-4] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
14 Horn S, Borrero-Wolff D, Ritter M, Arndts K, Wiszniewsky A, Debrah LB, Debrah AY, Osei-Mensah J, Chachage M, Hoerauf A, Kroidl I, Layland LE. Distinct Immune Profiles of Exhausted Effector and Memory CD8+ T Cells in Individuals With Filarial Lymphedema. Front Cell Infect Microbiol 2021;11:680832. [PMID: 34485170 DOI: 10.3389/fcimb.2021.680832] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Cuesta-Llavona E, Gómez J, Albaiceta GM, Amado-Rodríguez L, García-Clemente M, Gutiérrez-Rodríguez J, López-Alonso I, Hermida T, Enríquez AI, Hernández-González C, Gil-Peña H, Domínguez-Garrido E, Pérez-Oliveira S, Alvarez V, López-Larrea C, Suarez-Alvarez B, Tranche S, Jimeno-Demuth FJ, Coto E. Variant-genetic and transcript-expression analysis showed a role for the chemokine-receptor CCR5 in COVID-19 severity. Int Immunopharmacol 2021;98:107825. [PMID: 34116286 DOI: 10.1016/j.intimp.2021.107825] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
16 Hubacek JA, Dusek L, Majek O, Adamek V, Cervinkova T, Dlouha D, Pavel J, Adamkova V. CCR5Delta32 deletion as a protective factor in Czech first-wave COVID-19 subjects. Physiol Res 2021;70:111-5. [PMID: 33728925 DOI: 10.33549/physiolres.934647] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 11.0] [Reference Citation Analysis]
17 Ellwanger JH, Cardoso JDC, Chies JAB. Variability in human attractiveness to mosquitoes. Current Research in Parasitology & Vector-Borne Diseases 2021;1:100058. [DOI: 10.1016/j.crpvbd.2021.100058] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
18 Piasecki E. SARS-CoV-2: Remarks on the COVID-19 Pandemic. Arch Immunol Ther Exp (Warsz) 2020;68:35. [PMID: 33185755 DOI: 10.1007/s00005-020-00600-7] [Reference Citation Analysis]
19 Yeregui E, Viladés C, Domingo P, Ceausu A, Pacheco YM, Veloso S, Inciarte A, Vidal-González J, Peraire M, Perpiñán C, Falcó V, Masip J, Alba V, Vargas M, Martí A, Reverté L, Mallolas J, Vidal F, Peraire J, Rull A. High circulating SDF-1and MCP-1 levels and genetic variations in CXCL12, CCL2 and CCR5: Prognostic signature of immune recovery status in treated HIV-positive patients. EBioMedicine 2020;62:103077. [PMID: 33166788 DOI: 10.1016/j.ebiom.2020.103077] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
20 Gómez J, Cuesta-llavona E, Albaiceta GM, García-clemente M, López-larrea C, Amado-rodríguez L, López-alonso I, Hermida T, Enríquez AI, Gil H, Alonso B, Iglesias S, Suarez-alvarez B, Alvarez V, Coto E. The CCR5-delta32 variant might explain part of the association between COVID-19 and the chemokine-receptor gene cluster.. [DOI: 10.1101/2020.11.02.20224659] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
21 Mehlotra RK. Chemokine receptor gene polymorphisms and COVID-19: Could knowledge gained from HIV/AIDS be important? Infect Genet Evol 2020;85:104512. [PMID: 32858232 DOI: 10.1016/j.meegid.2020.104512] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
22 Mohan S, Mok S, Judge T. Identification of Novel Therapeutic Molecular Targets in Inflammatory Bowel Disease by Using Genetic Databases. Clin Exp Gastroenterol 2020;13:467-73. [PMID: 33116744 DOI: 10.2147/CEG.S264812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]